Mergers & Acquisitions Mergers & Acquisitions

Illumina-Grail deal draws in-depth EU review

By Natalie McNelis
  • 22 Jul 2021 11:46
  • 22 Jul 2021 11:48
Illumina’s $8 billion bid to buy cancer-testing start up Grail will face an in-depth investigation, the European Commission said today.
The European Commission said it's concerned that the deal may reduce competition and innovation in the emerging market for cancer-detection tests based on sequencing technologies.

“Cancer detection tests based

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Natalie McNelis

Senior Correspondent


Natalie McNelis covers mergers for MLex in Brussels. Before joining MLex in 2017, she spent 20 years as an international trade and competition lawyer in law firms including Stibbe and WilmerHale. Natalie has a BA in English from Mount Holyoke College, a JD from Harvard Law School and an LLM in EU law from KU Leuven. She is admitted to the bar in New York.

Discover MLex

Stay on top of global regulatory developments

Latest News